Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.

摘要: One hundred eighteen patients with metastatic carcinoid tumor were randomized to treatment streptozotocin combined cyclophosphamide or 5-fluorouracil (5-FU). Commonly experienced side effects nausea, vomiting, leukopenia, thrombocytopenia, and nephrotoxicity. Objective response rates among eligible evaluable treated the 5-FU combination was 14 of 42 (33%) combination, 12 47 (26%). Among those carcinoids primary small bowel respective 44% 37%. The overall for pulmonary unknown origin only 12% 17%. There no significant difference in patient survival between two arms. 11 who received crossover therapy alone there responders. responders eight alone. Urinary 5HIAA excretion proved be a useful biologic marker these that correlated well observed measurements bulk. Median times from diagnosis unresectable malignant disease related sites following: bowel, 28.4 months; pancreas, 24.0 lung, 15.1 origin, 9.0 months. Metastatic is susceptible chemotherapeutic approaches continued investigation neoplasms should strongly encouraged.